A seismic shift occurred today when the NELSON screening trial results were presented at the IASLC 19th World Conference on Lung Cancer (#WCLC2018). Hear from the CEO, Dr. Fred R. Hirsch, as he comments on these results. Men have a 24% survival advantage in the screening programme. This is a very large shift to earlier stage cancer detection. There can be no doubt that lung cancer screening is a lifesaving intervention in lung cancer.
You are here:
The NELSON Trial Reports Large Survival Advantage for Lung Cancer Screening in Europe
Submitted by: Joel Dunning
Source: International Association for the Study of Lung Cancer 19th World Conference on Lung Cancer
Source URL: https://www.youtube.com/watch?v=LwOP2cTfHyU
Keywords:
Author(s): Fred R. Hirsch
